Actavis rolls out generic Lidoderm patch; Daiichi shares plunge on new FDA import restrictions;

@FiercePharma: Now armed with EU nod for Lemtrada, Sanofi preps to launch its multiple sclerosis duo (with Aubagio). Release (PDF) | Follow @FiercePharma

@CarlyHFierce: Whistleblower codenamed Zorro implicates Novartis' Alcon division in Chinese bribery scandal. More from The Financial Times | Follow @CarlyHFierce

> Actavis ($ACT) launched its version of the Endo Pharmaceuticals ($ENDP) pain patch Lidoderm. Report

> Sanofi ($SNY) alerted U.K. doctors to a batch of Plavix patients that developed the rare autoimmune disease acquired hemophilia. Report

> Daiichi Sankyo stock plummeted after the FDA restricted imports from its Indian generics unit, Ranbaxy Laboratories. Report

> The German pharma company Aenova raised €130 million ($175 million) in financing to back its planned buyout of the contract manufacturer Haupt Pharma, Reuters reports. Report

> Bayer is amping up cost-cutting plans at its plastics unit at a time when its pharma business is delivering decent growth. Report

Medical Device News

@FierceMedDev: Special Report: 'Big' med tech M&A deals getting smaller. Feature | Follow @FierceMedDev

@DamianFierce: VisionCare landed up to $15M to market its AMD-treating eye implant. News | Follow @DamianFierce

@MarkHFierce: The U.S. will now have the first permanent implant designed to treat enlarged prostates. Expect a gradual launch. ICYMI yesterday | Follow @MarkHFierce

@MichaelGFierce: Abbott snags CE mark for diabetes monitor. Item | Follow @MichaelGFierce

> Europe risks more delays on device reg reform. More

> Medtronic cuts ribbon on $10M Irish R&D shop. Story

> Boston Scientific debuts teaching, R&D centers in China. Article

Biotech News

@FierceBiotech: ICYMI yesterday: CDC director warns antibiotics pipeline 'nearly empty.' Story | Follow @FierceBiotech

@JohnCFierce: Regado CEO moves the goal line after a rare biotech IPO misfire. More | Follow @JohnCFierce

> Biotechs keep the cash pumping (for now) with more IPOs and ATMs. Story

> On a roll, Boehringer wins 'breakthrough' status for pioneering leukemia drug. News

> Broker's Facebook rant on biotech stock draws $5K fine. Item

Pharma Manufacturing News

@EricPFierce: Now that Ranbaxy's Mohali plant falls under FDA consent decree, oversight ramps up significantly. Article | Follow @EricPFierce

> Cargill invests $15M in French alginate plant. Item

> Hospira recalls bupivacaine because of steel particles in vials. Story

> Strides gets FDA warning for plant Mylan is buying. More

> J&J sues Ben Venue over Doxil shortage. Report

Biotech Research News

@EmilyMFierce: Initial focus of BRAIN Initiative laid out, but are the goals any clearer than they were in April? Check out the story and weigh in | Follow @EmilyMFierce

> Visterra antibody shows promise in preclinical study as universal flu vaccine. Item

> NIH partners with Eli Lilly, others on rare diseases. Article

> Experimental vaccine clears monkeys of HIV-like virus. More

> Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. Story

And Finally... Drug-resistant bacteria are becoming a "nightmare," with urgent threats seen in three diseases. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.